Rong Deng Selected Research

pertuzumab

4/2022	Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
1/2021	Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rong Deng Research Topics

Disease

74	Neoplasms (Cancer) 05/2024 - 02/2006
18	Breast Neoplasms (Breast Cancer) 05/2024 - 01/2012
18	Infections 06/2023 - 09/2013
10	Neoplasm Metastasis (Metastasis) 11/2023 - 08/2014
9	Triple Negative Breast Neoplasms 01/2024 - 01/2015
9	Carcinogenesis 01/2021 - 11/2008
8	Nasopharyngeal Carcinoma 01/2019 - 06/2007
7	Human Influenza (Influenza) 02/2022 - 01/2016
6	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 09/2017
6	Leukemia 01/2023 - 12/2005
5	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 07/2010
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 01/2018
4	Carcinoma (Carcinomatosis) 01/2022 - 01/2018
4	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 08/2014
4	Cytomegalovirus Infections (Inclusion Disease) 01/2018 - 04/2014
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 04/2024 - 12/2023
3	COVID-19 06/2023 - 10/2020
3	Adenocarcinoma of Lung 05/2022 - 01/2022
3	Stomach Neoplasms (Stomach Cancer) 01/2021 - 01/2018
3	Body Weight (Weight, Body) 01/2021 - 01/2011
3	Melanoma (Melanoma, Malignant) 11/2020 - 01/2018
3	Colonic Neoplasms (Colon Cancer) 01/2018 - 01/2012
3	Osteosarcoma (Osteogenic Sarcoma) 02/2008 - 07/2007
3	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 06/2007 - 11/2005
3	Thrombocytopenia (Thrombopenia) 06/2007 - 11/2005
2	Myocardial Infarction 10/2023 - 01/2023
2	Stroke (Strokes) 10/2023 - 10/2020
2	Inflammation (Inflammations) 02/2023 - 05/2018
2	Lung Neoplasms (Lung Cancer) 01/2023 - 11/2021
2	Nausea 02/2022 - 01/2020
2	Liver Neoplasms (Liver Cancer) 01/2021 - 01/2018
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 12/2019

Drug/Important Bio-Agent (IBA)

14	Monoclonal AntibodiesIBA 10/2022 - 03/2007
12	Proteins (Proteins, Gene)FDA Link 10/2021 - 02/2006
9	Biomarkers (Surrogate Marker)IBA 02/2023 - 08/2011
8	MicroRNAs (MicroRNA)IBA 01/2022 - 07/2015
8	Phosphotransferases (Kinase)IBA 12/2021 - 04/2009
7	gedivumabIBA 02/2022 - 01/2016
6	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2016
6	DNA (Deoxyribonucleic Acid)IBA 12/2023 - 01/2012
5	Small Interfering RNA (siRNA)IBA 12/2022 - 02/2006
5	Hemagglutinins (Hemagglutinin)IBA 02/2022 - 01/2016
5	CytokinesIBA 10/2021 - 09/2015
5	Long Noncoding RNAIBA 01/2021 - 08/2014
5	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 03/2007
5	GoldIBA 01/2019 - 01/2017
4	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2024 - 11/2007
4	Rituximab (Mabthera)FDA Link 04/2024 - 07/2013
4	RNA (Ribonucleic Acid)IBA 07/2023 - 01/2021
4	IronIBA 01/2023 - 07/2014
4	Beclin-1IBA 12/2021 - 11/2008
4	LigandsIBA 10/2021 - 10/2009
4	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2021 - 07/2010
4	AntibodiesIBA 12/2020 - 11/2005
4	RG7667IBA 11/2018 - 08/2015
4	AgarIBA 01/2018 - 10/2017
3	polatuzumab vedotinIBA 04/2024 - 12/2023
3	Tumor Suppressor Protein p14ARF (p14ARF)IBA 12/2023 - 07/2007
3	Indicators and Reagents (Reagents)IBA 06/2023 - 09/2015
3	ErbB Receptors (EGF Receptor)IBA 01/2023 - 12/2018
3	venetoclaxIBA 01/2023 - 12/2019
3	Tyrosine Kinase InhibitorsIBA 01/2023 - 07/2015
3	Intravenous Immunoglobulins (IVIG)FDA Link 10/2022 - 03/2007
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2021 - 08/2012
3	Histone DemethylasesIBA 02/2021 - 12/2017
3	CateninsIBA 09/2019 - 11/2013
3	TOR Serine-Threonine KinasesIBA 03/2015 - 08/2012
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 03/2015 - 08/2012
3	hirsutanol AIBA 02/2013 - 07/2010
3	rhabdastrellic acid AIBA 08/2010 - 08/2007
3	Inosine Triphosphate (ITP)IBA 06/2007 - 11/2005
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2024 - 01/2022
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 12/2023 - 10/2021
2	Small Cytoplasmic RNAIBA 06/2023 - 01/2023
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2023 - 01/2023
2	CreatinineIBA 01/2023 - 12/2020
2	6-methyladenineIBA 12/2022 - 01/2018
2	pertuzumabIBA 04/2022 - 01/2021
2	Trastuzumab (Herceptin)FDA Link 04/2022 - 01/2021
2	Complement System Proteins (Complement)IBA 01/2022 - 09/2021
2	atezolizumabIBA 11/2021 - 01/2016
2	Autophagy-Related Protein-1 HomologIBA 10/2021 - 08/2011
2	Glucose (Dextrose)FDA LinkGeneric 07/2021 - 03/2018
2	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 01/2021 - 01/2015
2	LipidsIBA 01/2021 - 03/2007
2	AlbuminsIBA 01/2021 - 11/2018
2	B7-H1 AntigenIBA 01/2021 - 11/2020
2	Histones (Histone)IBA 01/2021 - 12/2017
2	ChromatinIBA 01/2021 - 12/2017
2	human ERBB2 proteinIBA 12/2020 - 11/2019
2	Antiviral Agents (Antivirals)IBA 12/2020 - 10/2018
2	Polo-Like Kinase 1IBA 12/2020 - 01/2019
2	Oseltamivir (Tamiflu)FDA Link 11/2020 - 01/2020

Therapy/Procedure

27	Therapeutics 02/2024 - 03/2007
8	Drug Therapy (Chemotherapy) 01/2024 - 07/2007
7	Immunotherapy 05/2024 - 03/2007
3	Radiotherapy 01/2023 - 01/2022
3	Length of Stay 05/2022 - 01/2022
2	Chemoradiotherapy 01/2023 - 01/2022
2	Subcutaneous Injections 04/2022 - 01/2021